TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Completed · Phase 1
Conditions studied: Solid Tumor, Adult
In brief
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Key facts
- Study ID
- NCT04306900
- Run by
- Trishula Therapeutics, Inc.
- People needed
- 185
- Starts
- 2020-03-30
- Expected to finish
- 2024-03-27
- Last updated by the study team
- 2025-07-29
Who can join
Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth Research Institute — Scottsdale, Arizona, United States
- City of Hope Medical Center Clinical Trials Office — Duarte, California, United States
- University of Southern California — Los Angeles, California, United States
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- UCLA Hematology/Oncology — Los Angeles, California, United States
- Chao Family Comprehensive CC, UCI — Orange, California, United States
- UC Davis Comprehensive Cancer Center — Sacramento, California, United States
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine — Miami, Florida, United States
- Ocala Oncology Center PL — Ocala, Florida, United States
- Orlando Health UF Health Cancer Center — Orlando, Florida, United States
- IACT Health - John B. Amos Cancer Center — Columbus, Georgia, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Ochsner Medical Center — New Orleans, Louisiana, United States
- Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska, United States
- Montefiore Medical Center — The Bronx, New York, United States
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
- University of Toledo — Toledo, Ohio, United States
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
- Prisma-Health Cancer Institute — Greenville, South Carolina, United States
- West Cancer Center and Research Institute — Germantown, Tennessee, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- NEXT Oncology — San Antonio, Texas, United States
- Hunstman Cancer Intitute — Salt Lake City, Utah, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.